Investor Overview

NASDAQ: XBIT0.003.44Data provided by Nasdaq.
Minimum 15 minutes delayed.

XBiotech is building on a foundation of remarkable new therapies, innovative approaches to commercialization and a commitment to realizing treatments for unmet medical needs worldwide.

Recent News
DateTitle 
10/05/18XBiotech Announces Enrollment Completion in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Atopic DermatitisPrinter Friendly Version
09/26/18XBiotech Announces Granting of European Patent for Treatment of Inflammatory Skin DiseasesPrinter Friendly Version
09/24/18XBiotech Announces Completion of U.S. Enrollment in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Hidradenitis SuppurativaPrinter Friendly Version

Read more »

Upcoming Events

There are currently no events scheduled.

Read more »